Reporter March 5 2021
Mar. 4, 2021—A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
Mar. 4, 2021—Adolescents and young adults living with HIV in Middle Tennessee are being ushered into adult care through a special transition clinic that focuses on adult skill-building and individualized therapy and discussions.
Mar. 4, 2021—When the COVID-19 pandemic hit in 2020, members of the Vanderbilt Health Affiliated Network (VHAN) — a clinically integrated network in Tennessee and surrounding states that now includes more than 6,100 clinicians, 70 hospitals, 13 health systems and hundreds of physician practices and clinics — were hit with challenges they might have never previ
Mar. 4, 2021—In December 2020, the federal government’s massive precision medicine research initiative, All of Us (AoU), made available to qualified researchers initial results from its ongoing COVID-19 Participant Experience (COPE) Survey, as well as physical activity and heart rate data collected from Fitbit devices worn by AoU participants.
Mar. 4, 2021—David DeMets, PhD, known for his work on statistical methods to monitor interim clinical trial data for early evidence of benefit or harm, will deliver the next web-based Discovery Lecture.
Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.
Mar. 3, 2021—After two years of planning and regulatory approvals, Vanderbilt University Medical Center is preparing to launch a durable medical equipment (DME) company, Carefluent Connect, LLC.